Phase 4 Completed N=752 Randomized Single-blind Treatment

Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

Rheumatoid Arthritis

Source: ClinicalTrials.gov NCT00245960 ↗

Enrolled (actual)

752

Serious AEs

—

Results posted

May 2009

Primary outcomePrimary: Number of Patients Achieving "Clear" or "Almost Clear" on Physician Global Assessment (PGA) of Psoriasis — 176; 119 participants

Summary

The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Patients Achieving "Clear" or "Almost Clear" on Physician Global Assessment (PGA) of Psoriasis	176; 119	—
SECONDARY Number of Patients Achieving Psoriatic Arthritis Response Criteria (PsARC)	284; 282; 303; 299	—

Eligibility Criteria

Inclusion Criteria

18 years of age or older at time of consent
Active Psoriatic Arthritis
Clinically stable, plaque psoriasis involving more than 10% of the body surface area

Exclusion Criteria

Evidence of skin conditions other than psoriasis that would interfere with skin examinations.
Systemic anti-psoriasis therapy or DMARD within 28 days of study drug initiation
Prior exposure to any TNF-inhibitor, including etanercept

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00245960). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.